Adenosine A2A receptor gene expression in the normal striatum and after 6-OH-dopamine lesion

Adenosine A2A receptor gene expression in the normal striatum and after 6-OH-dopamine lesion
复制标题

DOI:
10.1007/s007020070037
复制
发表时间:
2000-01-01
影响因子:
3.3
通讯作者:
Burgunder, JM
Burgunder, JM
中科院分区:
医学3区
文献类型:
--
作者:
Kaelin-Lang, A;Liniger, P;Burgunder, JM

文献摘要

被引文献

相似文献

腺苷A(2A)受体存在于大鼠脑啡能中等大小纹状体神经元上,在纹状体输出调节中起重要作用。为了更准确地确定腺苷传递是否在哺乳动物纹状体中是一种普遍现象,我们比较了小鼠、大鼠、猫和人类纹状体中的a (2A) R表达。其次比较6- oh -多巴胺损伤大鼠黑质后纹状体神经元脑啡肽基因和A(2A)受体基因表达的变化。用s -35标记的放射性寡核苷酸探针进行杂交组织化学。结果显示,A(2A)腺苷受体基因仅在纹状体中等大小的细胞中高表达。在大鼠纹状体中,6- oh -多巴胺损伤多巴胺能通路后,尽管脑啡肽基因表达上调,但A(2A)受体的表达没有明显改变。6- oh -多巴胺治疗后,a (2A)受体基因表达没有变化,这与多巴胺能神经支配的依赖性相反。在多巴胺耗竭的情况下,A(2R) R维持对运动活动的抑制功能可能是在帕金森病等基底神经节疾病中观察到的运动活动抑制的部分原因。
Adenosine A(2A) receptors are present on enkephalinergic medium sized striatal neurons in the rat and have an important function in the modulation of striatal output. In order to establish more accurately whether adenosine transmission is a generalized phenomenon in mammalian striatum we compared the A(2A) R expression in the mouse, rat, cat and human striatum. Secondly we compared the modulation of enkephalin gene expression and A(2A) receptor gene expression in rat striatal neurons after 6-OH-dopamine lesion of the substantia nigra. Hybridization histochemistry was performed with a S-35-labelled radioactive oligonucleotide probe. The results showed high expression of A(2A) adenosine receptor genes only in the medium-sized cells of the striatum in all examined species. In the rat striatum, expression of A(2A) receptors was not significantly altered after lesion of the dopaminergic pathways with 6-OH-dopamine even though enkephalin gene expression was up-regulated. The absence of a change in A(2A) receptor gene expression after 6-OH-dopamine treatment speaks against a dependency on dopaminergic innervation. The maintained inhibitory function of A(2R) R on motor activity in spite of dopamine depletion could be partly responsible for the depression of locomotor activity observed in basal ganglia disorders such as Parkinson's disease.